[{"address1": "3655 Nobel Drive", "address2": "Suite 260", "city": "San Diego", "state": "CA", "zip": "92122", "country": "United States", "phone": "858 926 7655", "website": "https://darebioscience.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Dar\u00e9 Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies. In addition, the company develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable formulations of etonogestrel that provides contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. Further, it develops DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design controlled contraceptive option; DARE-RH1, an approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein; DARE-LBT, a vaginal thermosetting gel formulation for the delivery of live biotherapeutics; and DARE-GML, which delivers antimicrobial glycerol monolaurate intravaginally. Dar\u00e9 Bioscience, Inc. was founded in 2015 and is headquartered in San Diego, California.", "fullTimeEmployees": 21, "companyOfficers": [{"maxAge": 1, "name": "Ms. Sabrina Martucci Johnson", "age": 57, "title": "CEO, President, Principal Financial Officer, Secretary & Director", "yearBorn": 1967, "fiscalYear": 2024, "totalPay": 641406, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. MarDee J. Haring-Layton", "age": 48, "title": "Chief Accounting Officer", "yearBorn": 1976, "fiscalYear": 2024, "totalPay": 409800, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mark  Walters", "age": 69, "title": "Vice President of Operations", "yearBorn": 1955, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David  Friend Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.63, "open": 1.64, "dayLow": 1.61, "dayHigh": 1.685, "regularMarketPreviousClose": 1.63, "regularMarketOpen": 1.64, "regularMarketDayLow": 1.61, "regularMarketDayHigh": 1.685, "payoutRatio": 0.0, "beta": 0.766, "forwardPE": -1.2352941, "volume": 86819, "regularMarketVolume": 86819, "averageVolume": 142982, "averageVolume10days": 113410, "averageDailyVolume10Day": 113410, "bid": 1.63, "ask": 1.71, "bidSize": 1, "askSize": 1, "marketCap": 22645562, "fiftyTwoWeekLow": 1.61, "fiftyTwoWeekHigh": 9.19, "allTimeHigh": 1304.4, "allTimeLow": 1.62, "priceToSalesTrailing12Months": -396.38654, "fiftyDayAverage": 2.0226, "twoHundredDayAverage": 2.5525, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 3863189, "profitMargins": 0.0, "floatShares": 12741563, "sharesOutstanding": 13479502, "sharesShort": 221779, "sharesShortPriorMonth": 207710, "sharesShortPreviousMonthDate": 1759190400, "dateShortInterest": 1761868800, "sharesPercentSharesOut": 0.0165, "heldPercentInsiders": 0.10831001, "heldPercentInstitutions": 0.07073, "shortRatio": 1.22, "shortPercentOfFloat": 0.0166, "impliedSharesOutstanding": 13479502, "bookValue": 0.205, "priceToBook": 8.195122, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -17463954, "trailingEps": -1.83, "forwardEps": -1.36, "lastSplitFactor": "1:12", "lastSplitDate": 1719792000, "enterpriseToRevenue": -67.621, "enterpriseToEbitda": -0.236, "52WeekChange": -0.4874214, "SandP52WeekChange": 0.09209216, "quoteType": "EQUITY", "currentPrice": 1.68, "targetHighPrice": 12.0, "targetLowPrice": 8.0, "targetMeanPrice": 10.75, "targetMedianPrice": 11.5, "recommendationMean": 1.25, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 4, "totalCash": 23075260, "totalCashPerShare": 1.615, "ebitda": -16362804, "totalDebt": 2932546, "quickRatio": 1.105, "currentRatio": 1.179, "totalRevenue": -57130, "debtToEquity": 102.612, "revenuePerShare": -0.006, "returnOnAssets": -0.4474, "returnOnEquity": -25.431341, "grossProfits": -14354664, "freeCashflow": -938184, "operatingCashflow": -6103524, "revenueGrowth": -0.946, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -1623.4077, "financialCurrency": "USD", "symbol": "DARE", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": 3.06748, "regularMarketPrice": 1.68, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1397136600000, "postMarketChangePercent": -3.869044, "postMarketPrice": 1.615, "postMarketChange": -0.06499994, "regularMarketChange": 0.05, "regularMarketDayRange": "1.61 - 1.685", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 142982, "fiftyTwoWeekLowChange": 0.06999993, "fiftyTwoWeekLowChangePercent": 0.04347822, "fiftyTwoWeekRange": "1.61 - 9.19", "fiftyTwoWeekHighChange": -7.5099998, "fiftyTwoWeekHighChangePercent": -0.8171926, "fiftyTwoWeekChangePercent": -48.742138, "dividendDate": 1500508800, "earningsTimestamp": 1763067600, "earningsTimestampStart": 1763067600, "earningsTimestampEnd": 1763067600, "earningsCallTimestampStart": 1763069400, "earningsCallTimestampEnd": 1763069400, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -1.83, "epsForward": -1.36, "epsCurrentYear": -1.655, "corporateActions": [], "postMarketTime": 1763764392, "regularMarketTime": 1763758801, "exchange": "NCM", "messageBoardId": "finmb_423979060", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "shortName": "Dare Bioscience, Inc.", "longName": "Dar\u00e9 Bioscience, Inc.", "marketState": "CLOSED", "priceEpsCurrentYear": -1.0151057, "fiftyDayAverageChange": -0.3426, "fiftyDayAverageChangePercent": -0.16938594, "twoHundredDayAverageChange": -0.87250006, "twoHundredDayAverageChangePercent": -0.34182176, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.3 - Strong Buy", "cryptoTradeable": false, "displayName": "Dar\u00e9 Bioscience", "trailingPegRatio": null, "__fetch_time": "2025-11-22"}]